[奈玛特韦/利托那韦（帕罗韦德®），一种治疗新冠病毒病的药物]
[Nirmatrelvir/ritonavir (Paxlovid®), a treatment for Covid-19].
作者信息
Buxeraud Jacques, Faure Sébastien, Fougere Édouard
机构信息
Faculté de pharmacie, 2 rue du Docteur-Marcland, 87025 Limoges cedex, France.
Département Pharmacie, Faculté de santé, université d'Angers, 16 boulevard Daviers, 49045 Angers, France.
出版信息
Actual Pharm. 2022 Jun;61(617):10-12. doi: 10.1016/j.actpha.2022.05.002. Epub 2022 Jul 22.
Abstract
The nirmatrelvir-ritonavir (Paxlovid®) is a treatment against Covid-19 available in pharmacies since February 4, 2022. Administered orally, it is intended only for people at very high risk of contracting one or more severe forms of the disease.
摘要
奈玛特韦-利托那韦（Paxlovid®）是一种自2022年2月4日起在药店可购得的针对新冠病毒病的治疗药物。口服给药，仅适用于感染一种或多种严重疾病形式风险极高的人群。
相似文献
1
[Nirmatrelvir/ritonavir (Paxlovid®), a treatment for Covid-19].[奈玛特韦/利托那韦（帕罗韦德®），一种治疗新冠病毒病的药物]
Actual Pharm. 2022 Jun;61(617):10-12. doi: 10.1016/j.actpha.2022.05.002. Epub 2022 Jul 22.
2
Paxlovid mouth likely is mediated by activation of the TAS2R1 bitter receptor by nirmatrelvir.奈玛特韦通过激活 TAS2R1 苦味受体发挥作用。
Biochem Biophys Res Commun. 2023 Nov 19;682:138-140. doi: 10.1016/j.bbrc.2023.10.001. Epub 2023 Oct 2.
3
Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?口服奈玛特韦/利托那韦治疗新冠病毒病：黑暗中的曙光？
Antibiotics (Basel). 2022 Feb 9;11(2):220. doi: 10.3390/antibiotics11020220.
4
Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant.COVID-19 感染患儿在使用奈玛特韦/利托那韦（Paxlovid）治疗后，他的他克莫司水平升高。
Pediatr Nephrol. 2023 Apr;38(4):1387-1388. doi: 10.1007/s00467-022-05712-0. Epub 2022 Aug 19.
5
Paxlovid (Nirmatrelvir and Ritonavir) Use in Pregnant and Lactating Woman: Current Evidence and Practice Guidelines-A Scoping Review.帕罗韦德（奈玛特韦和利托那韦）在孕妇和哺乳期妇女中的应用：当前证据与实践指南——一项范围综述
Vaccines (Basel). 2023 Jan 1;11(1):107. doi: 10.3390/vaccines11010107.
6
The history, mechanism, and perspectives of nirmatrelvir (PF-07321332): an orally bioavailable main protease inhibitor used in combination with ritonavir to reduce COVID-19-related hospitalizations.奈玛特韦（PF-07321332）的历史、作用机制及前景：一种口服生物利用度良好的主要蛋白酶抑制剂，与利托那韦联合使用以减少与COVID-19相关的住院治疗。
Med Chem Res. 2022;31(10):1637-1646. doi: 10.1007/s00044-022-02951-6. Epub 2022 Aug 30.
7
COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature.帕罗韦德治疗后新冠病毒感染的反弹：病例系列及文献综述
Cureus. 2022 Jun 23;14(6):e26239. doi: 10.7759/cureus.26239. eCollection 2022 Jun.
8
Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment - California, December 2021-May 2022.加利福尼亚州 2021 年 12 月至 2022 年 5 月辉瑞公司新冠口服药 Paxlovid 治疗后因 COVID-19 住院和急诊就诊情况。
MMWR Morb Mortal Wkly Rep. 2022 Jun 24;71(25):830-833. doi: 10.15585/mmwr.mm7125e2.
9
Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19.莫努匹拉韦和奈玛特韦-利托那韦与轻度至中度COVID-19高危患者的可预防死亡率、住院率及相关可避免的医疗系统成本的关联
Lancet Reg Health West Pac. 2023 Jan;30:100602. doi: 10.1016/j.lanwpc.2022.100602. Epub 2022 Oct 5.
10
Paxlovid with Caution: Novel Case of Paxlovid-Induced Tacrolimus Toxicity in a Cardiac Transplant Patient.谨慎使用帕罗韦德：心脏移植患者中帕罗韦德诱发他克莫司毒性的新病例
Eur J Case Rep Intern Med. 2022 Sep 16;9(9):003528. doi: 10.12890/2022_003528. eCollection 2022.
引用本文的文献
1
Leveraging SARS-CoV-2 Main Protease (M) for COVID-19 Mitigation with Selenium-Based Inhibitors.利用 SARS-CoV-2 主要蛋白酶（M）与基于硒的抑制剂减轻 COVID-19。
Int J Mol Sci. 2024 Jan 12;25(2):971. doi: 10.3390/ijms25020971.
2
Antiviral Activity of Acetylsalicylic Acid against Bunyamwera Virus in Cell Culture.乙酰水杨酸对细胞培养中 Bunyamwera 病毒的抗病毒活性。
Viruses. 2023 Apr 11;15(4):948. doi: 10.3390/v15040948.
Zotero 插件